Popular terms

Aspirin topics
Acetylsalicylic Acid
Cardiovascular Disease
Cardiovascular
Vascular Disease
Calcium Carbonate
Nitroglycerin
Epinephrine
Eicosapentaenoic Acid
Docosahexaenoic Acid
Polyunsaturated Fatty Acid
Fondaparinux
Bivalirudin
Paclitaxel
Salicylic Acid
Vascular Diseases

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Aspirin patents



      

This page is updated frequently with new Aspirin-related patent applications.




Date/App# patent app List of recent Aspirin-related patents
05/26/16
20160143922 
 Anti-flush compositions patent thumbnailnew patent Anti-flush compositions
Disclosed are pharmaceutical compositions having a portion of aspirin for intraoral release and another aspirin for gastrointestinal release. The compositions can further include niacin.
Vitalis Llc


05/05/16
20160122991 
 Toilet water splash inhibiting device patent thumbnailToilet water splash inhibiting device
A toilet water splash inhibiting device for inhibit splashing of toilet water during evacuation of waste into a toilet. The device includes a mixture of liquid body soap, baking soda, vinegar, sodium bicarbonate, aspirin, and anhydrous citric acid..

04/21/16
20160107002 
 Ischemic stroke therapy patent thumbnailIschemic stroke therapy
A method for delivering ultrasound energy to a patient's intracranial space includes the steps of forming a hole in a patient's skull, locating an ultrasound transmitter near or into the hole, and transmitting ultrasound from the transmitter into the intracranial space, wherein the mechanical index of ultrasound energy traveling through cerebral tissue in the intracranial space is less than 1.0, the power intensity delivered to a target tissue in the intracranial space is greater than 50 mw/cm2 and less than 200 mw/cm2, and the frequency of the transmitted ultrasound is within the range between 500 khz and 2 mhz. Microbubbles, aspirin, both microbubbles and aspirin, and a mixture of microbubbles and aspirin, can also be delivered into the intracranial space,.

03/10/16
20160068468 
 Novel aspirin derivatives and uses thereof patent thumbnailNovel aspirin derivatives and uses thereof
The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer..
North Carolina Agricultural And Technical State University


01/28/16
20160022575 
 System for administration of cardiac protective therapy patent thumbnailSystem for administration of cardiac protective therapy
An dosage member, comprising a planar member comprising a saliva-dissolvable member, a therapeutic agent carried in said planar member, wherein the saliva-dissolvable member is printed or color-coded to indicate potency. A plurality of aspirin containing dissolvable members may each be color-coded to indicate potency, and include a plurality of green dissolvable members and at least one dissolvable member with a color selected from the group consisting of yellow or amber, a red or red like color and a blue or blue like color.

12/31/15
20150374835 
 Liquid topical pharmaceutical nano-emulsion formulations patent thumbnailLiquid topical pharmaceutical nano-emulsion formulations
Aspects of the present invention are directed to compositions that are useful for delivery of an active ingredient to a subject. Some embodiments are formulated with an active ingredient, including, for example, a non-steroidal anti-inflammatory drug (nsaid), such as aspirin, ibuprofen, ketoprofen, or naproxen, acetaminophen, or a polypeptide or protein, such as insulin, wherein the active ingredient is stabilized and greater than 90% of the particles of the active ingredient have a particle size that is less than or equal to or any number in between 100, 90, 80, 70, 60, 50, 40, 30, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, or 4 nanometers, or smaller, as determined by dynamic light scattering (dls), using a volume-weighted particle size distribution calculation method..
Jrx Biotechnology, Inc.


12/17/15
20150359808 
 Compositions and methods for reducing hepatotoxicity associated with drug administration patent thumbnailCompositions and methods for reducing hepatotoxicity associated with drug administration
The present invention relates to the discovery that acetylsalicylic acid (asa or aspirin), salicylic acid (sa) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound..
Yale University


12/10/15
20150352129 
 Aspirin formulation for increased efficacy patent thumbnailAspirin formulation for increased efficacy
Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof.
Vitalis Llc


11/19/15
20150328162 
 Pharmaceutical preparations patent thumbnailPharmaceutical preparations
The present invention relates to an improved pharmaceutical preparation comprising a dosage form of an active ingredient such as aspirin, acetaminophen, ibuprofen, naproxen sodium salt, or other nsaid, in the form of an easily chewable tablet, which when chewed is rapidly absorbed into the blood stream by the intimate presence of citric acid to yield desirably fast high blood levels.. .

11/12/15
20150320792 
 Remedy for gastritis and gastric ulcer patent thumbnailRemedy for gastritis and gastric ulcer
Provided is a gastritis and gastric ulcer-treating agent, which is prepared and developed by processing solar salt and bamboo tree into heat-treated purple salt, in which the heat-treated salt, which is prepared by firstly heat-treating mineral rich solar salt and bamboo tree at a high temperature, that is, 1,100° c. Or more; and two or more time repeating the heat-treating of the first heat-treated salt and bamboo tree under the above-described conditions, includes a large amount of hydrogen sulfide-producing material and has a purple color, and when the heat-treated salt is used along with aspirin, the heat-treated salt has an excellent effect on preventing stomach damage, thereby significantly reducing bleeding, ulcer, and the damage of mucous membrane, induced by aspirin..
Mokpo National University Industry-academia Cooperation Group


10/15/15
20150291615 

Compounds with super-aspirin effects


A compound having the structural formula (i) and pharmaceutically acceptable salt and/or hydrates thereof, (i) wherein y is an arylester or an c1-c8 alkylaryl ester, selected from the group consisting of: benzene, toluene, xylene, benzoic acid, benzoate, nicotinate, isonicotinate and halobenzene, which can be unsubstituted or substituted with at least one nitric oxide releasing group; and/or at least one of hydroxide, —cl, —br, a c1-c8 alkyl, benzyl, a c1-c8 alkoxy, benzyloxy, —nhc(o)r, —nh2, —no2, —ono2, —(ch2)n ono2, —oc(o)[(ch2)m], cyclic ono2, —ocoarono2, —ocoar(ch2)n ono2 or a c1-c5 haloalkyl ester, wherein r is a c1-c8 alkyl or a c1-c8 alkoxy group, n=1-8 and m=3-10, to produce a super-aspirin effect.. .

09/10/15
20150253327 

Diagnosis and treatment of aspirin-exacerbated respiratory disease (aerd)


Described herein are assays and methods relating to the diagnosis, prognosis, and treatment of aspirin-exacerbated respiratory disease (aerd) by detecting and/or measuring the level of platelet-bound leukocytes in a subject or a sample obtained from a subject.. .
Brigham And Women's Hospital, Inc.


09/10/15
20150250844 

Formulations from natural products, turmeric, paclitaxel, and aspirin


The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.. .

08/13/15
20150226756 

Dual anti-platelet medication/aspirin response and reactivity test using synthetic collagen


The present invention provides tests that measures functional platelet aggregation such as by using light transmission aggregometry assays (ltaas) or flow cytometry, using synthetic, self-assembling human type i collagen, methods of predicting and measuring an individual's platelet anti-platelet medication sensitivity and residual platelet activity status when the individual is on a dual anti-platelet therapy of aspirin and anti-platelet medication and kits useful in the assays and methods.. .
Jnc Corporation


06/18/15
20150164818 

Sequential administration of partitioned absorption aspirin or active aspirin derivative and cox-2 inhibitor


Described herein are an aspirin or active aspirin derivative and a cox-2 inhibitor, at least one of which has an enteric or partial enteric coating, administered in combination yet delivered sequentially, for the treatment and prophylactic treatment of diseases, symptoms and conditions. In some embodiments, the cox-2 inhibitor has the enteric coating; however, the aspirin or active aspirin derivative may additionally or alternately have the enteric coating.

06/04/15
20150153369 

Sample processing system for processing biological samples


The invention relates to a sample processing system and method for processing biological samples, particularly bodily fluids like blood, saliva, secretions and the like or tissue samples, particularly for preparation of samples for a dna analysis by means of pcr, comprising a sample processing device (12) having: an receiving plate (14), wherein the receiving plate (14) is arranged substantially horizontally in a plane defined by a first and second direction (x, y); a first and second working arm (20, 22), wherein the first and second working arm (20, 22) can move relative to the receiving plate (14), preferably along a first edge (18) of the receiving plate (14) in the first direction (x), and wherein the first and second working arm (20, 22) extend substantially parallel to each other in the second direction (y) over the receiving plate (14), wherein at least one pipetting device (40, 42) is mounted on the first working arm (20) which is movable in the second direction (y) and in a third direction (z) orthogonal in relation to the first and second direction (x, y) and wherein at least one gripping device (50) is mounted on the second working arm (22) which is movable in the second direction (y) and in a third direction (z) orthogonal in relation to the first and second direction (x, y), wherein grippers (54) provided on the gripping device (50) can be rotated around a gripper axis of rotation (ga) parallel to the third direction (z); and a control device for controlling the pipetting device (40, 42) and the gripping device (50). The system further comprises a plurality of sample containers (68) filled with samples, particularly liquid samples, or fillable with samples or reagents, a plurality of pipetting tips (48) which can be used by means of the pipetting device (48) for aspiring and dispensing sample fluid or additional reagents required for the sample processing, such as a lysis buffer, wherein the sample containers (68) and the pipetting tips (48) are arranged on the receiving plate (14) by means of corresponding sample container carriers (64, 66) and/or pipetting tip carriers (44).
Hamilton Bonaduz Ag


03/26/15
20150087590 

Diaspirin crosslinked pegylated hemoglobin


Pegylated diaspirin-crosslinked hemoglobin conjugates having high oxygen affinity are described which have enhanced nitrite reductase activity to deliver oxygen, carbon monoxide, nitric oxide or mixtures thereof to tissues to treat various diseases and conditions.. .
Sangart, Inc.


03/19/15
20150079169 

Controlled dosing of clopidogrel with gastric acid inhibition therapies


The present invention provides for novel formulations of clopidogrel in combination with proton pump inhibitors (ppi) and optionally with nsaids, for use as improved antiplatelet therapies in stroke and cardiovascular indications. The invention provides the delivery of clopidogrel in pulses or waves, such that the total dose is phased/spread out over time and, advantageously, combined with omeprazole in a way to minimize the conflicting actions these two drugs may have on each other.
Pozen Inc.


03/12/15
20150072005 

Aspirin formulation for increased efficacy


Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof.
Vitalis Llc


10/30/14
20140322328 

Dry powder formulations and methods of use


The subject technology relates generally to pulmonary delivery of nsaids, such as aspirin.. .

09/04/14
20140248352 

Chewable enteric coated aspirin tablets


The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated aspirin active ingredient, and preferably a lightly compressed matrix comprising directly compressible carbohydrate(s) and at least one sweetener.. .

08/07/14
20140220694 

Methods and compositions relating to platelet sensitivity


The invention identifies and describes proteins that are differentially expressed in platelets resistant to anti-platelet agents such as aspirin (acetylsalicyclic acid) compared to those platelets that are sensitive to such agents. Methods for determining further such differentially expressed proteins and methods for determining an individual's sensitivity to anti-platelet agents, such as aspirin, prior to administration..

06/26/14
20140179630 

Use of docasatrienes, resolvins, and their stable analogs in the treatment of airway diseases and asthma


The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (pufa) such as eicosapentaenoic acid (epa) or docosahexaenoic acid (dha), cyclooxygenase-ii (cox-2) and an analgesic, such as aspirin (asa). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy epa or dha compounds having unique structural and physiological properties.

04/03/14
20140094519 

Lipoxin analogs as novel inhibitors of angiogenesis


The present invention is generally drawn to novel isolated therapeutic agents, termed lipoxins, generated from the interaction between a dietary omega-6 polyunsaturated fatty acid (pufa) such as arachidonic acid (aa), oxygenases and the analgesic aspirin (asa). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy containing derivatives of aa containing compounds having unique structural and physiological properties.

03/06/14
20140066413 

Analgesic composition and making the same


A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solubilizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of analgesia..

01/23/14
20140024681 

Compounds with super-aspirin effects


A compound having the structural formula (i) and pharmaceutically acceptable salt and/or hydrates thereof, (i) wherein y is an arylester or an c1-c8 alkylaryl ester, selected from the group consisting of: benzene, toluene, xylene, benzoic acid, benzoate, nicotinate, isonicotinate and halobenzene, which can be unsubstituted or substituted with at least one nitric oxide releasing group; and/or at least one of hydroxide, —cl, —br, a c1-c8 alkyl, benzyl, a c1-c8 alkoxy, benzyloxy, —nhc(o)r, —nh2, —no2—ono2, —(ch2)nono2, —oc(o)[(ch2)n]cyclicono2, —ocoarono2, —ocoar(ch2)nono2 or a c1-c5 haloalkyl ester, wherein r is a c1-c8 alkyl or a c1-c8 alkoxy group, n=1-8 and m=3-10, to produce a super-aspirin effect.. .

12/19/13
20130338120 

Aspirin derivatives and uses thereof


The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer..

09/19/13
20130243872 

Pharmaceutical composite formulation comprising hmg-coa reductase inhibitor and aspirin


Provided is a pharmaceutical composite formulation for preventing or treating cardiovascular diseases, which comprises (1) a first particle comprising an hmg-coa reductase inhibitor and a basic additive; and (2) a second particle comprising a core containing aspirin and an enteric coating layer coated on said core, wherein the difference in the average diameters of said first and second particles is 100 μm to 800 μm; a method for preparing same; and a method of validating the quality of same. The pharmaceutical composite formulation according to the present invention can improve the stability of an active ingredient and prevent adverse impacts between the active ingredients to thereby enable an accurate quality validation of the pharmaceutical composite formulation..

09/19/13
20130243859 

Orally disintegrating tablet


The present invention relates to a multi-layer orally disintegrating tablet having (1) an enteric fine granule-containing layer containing a proton pump inhibitor and (2) an acetylsalicylic acid-containing layer, which shows high stability of the active ingredients (proton pump inhibitor, aspirin) and expresses the pharmacological effects of the active ingredients stably and rapidly after administration.. .

08/22/13
20130217771 

Resolvins: bioemplates for novel therapeutic interventions


The present invention is generally drawn to novel isolated therapeutic agents, termed resolvins, generated from the interaction between a dietary omega-3 polyunsaturated fatty acid (pufa) such as eicosapentaenoic acid (epa) or docosahexaenoic acid (dha), cyclooxygenase-ii (cox-2) and an analgesic, such as aspirin (asa). Surprisingly, careful isolation of compounds generated from the combination of components in an appropriate environment provide di- and tri-hydroxy epa or dha compounds having unique structural and physiological properties.

08/15/13
20130209441 

Process for inhibition of cerebral damage associated with ischemia by anthocyanins and anthocyanidins


A composition is also provided that includes ananthocyanin compound to cause blood clot dissolution. The agent being in specific embodiments is tissue plasminogen activator or aspirin..

07/25/13
20130186779 

Blister pack for a container


The present invention relates to a blister pack sealed to the neck of a container and adapted to fit under the container lid forming a seal, said blister pack containing a liquid soluble material such as dissolvable aspirin. When force is applied to the blister pack, the base, which is comprised of a rupturable material, breaks and allows the liquid soluble material to be mixed with the liquid in the container.

05/16/13
20130122098 

Method and composition to improve absorption of therapeutic agents


A tablet with an enhanced dissolution profile for a medicinally active ingredient such as aspirin and methods for making the tablet. The tablet comprises a blend of crystals of the medicinally active ingredient and a dissolution aid such as sodium or calcium carbonate or bicarbonate that coats the crystals upon co-milling.

05/09/13
20130115289 

Anti-flush compositions


Disclosed are pharmaceutical compositions having a portion of aspirin for intraoral release and another aspirin for gastrointestinal release. The compositions can further include niacin.

02/14/13
20130040898 

Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof


The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to treatment or prevention of ischemic events in patients with cardiovascular disease. The present invention is particularly useful for patients having or being at increased risk of development of an ischemic event such as an acute myocardial infarction and/or no-reflow phenomena and/or ischemia-reperfusion injury by administration of agent(s) modulating and/or preserving endothelial integrity.

02/07/13
20130035317 

Di-aspirin derivatives


The invention relates to the use of di-aspirin (bis(2-carboxyphenyl)succinate) and its derivatives in the treatment of colon and colorectal cancer. It also relates to novel derivatives of di-aspirin and to a method of synthesis of the di-aspirin and its derivatives..

01/31/13
20130029922 

Formulations from natural products, turmeric, paclitaxel, and aspirin


The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.. .



Aspirin topics: Acetylsalicylic Acid, Cardiovascular Disease, Cardiovascular, Vascular Disease, Calcium Carbonate, Nitroglycerin, Epinephrine, Eicosapentaenoic Acid, Docosahexaenoic Acid, Polyunsaturated Fatty Acid, Fondaparinux, Bivalirudin, Paclitaxel, Salicylic Acid, Vascular Diseases

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Aspirin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Aspirin with additional patents listed. Browse our RSS directory or Search for other possible listings.


5.7274

1631

469300 - 0 - 38